Glutamine

Glutamine

SCHEMBL2482060

C[C@@H](O)[C@H](N)C(=O)O.NC(=O)CC[C@H](N)C(=O)O

nearest known ligand 0.70

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.70
PMP22 Q01453 2/20 0.70
ALOX15 P16050 1/20 0.70
BLM P54132 1/20 0.70
CYP1A2 P05177 2/20 0.50
GSR P00390 2/20 0.50
GRM8 O00222 1/20 0.50
GRM6 O15303 1/20 0.50
GRIN2D O15399 1/20 0.50
GRIN3B O60391 1/20 0.50
GRIK1 P39086 1/20 0.50
GRM5 P41594 1/20 0.50
GRIA1 P42261 1/20 0.50
GRIA2 P42262 1/20 0.50
GRIA3 P42263 1/20 0.50
SLC1A3 P43003 1/20 0.50
SLC1A2 P43004 1/20 0.50
SLC1A1 P43005 1/20 0.50
GRIA4 P48058 1/20 0.50
GRIN1 Q05586 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Glutamine SCHEMBL22501358 1.00 KMT2A (0.70) KMT2APMP22ALOX15BLMCYP1A2
Glutamine SCHEMBL2482055 1.00 KMT2A (0.70) KMT2APMP22ALOX15BLMCYP1A2
Glutamine SCHEMBL6691598 1.00 KMT2A (0.70) KMT2APMP22ALOX15BLMCYP1A2
Glutamine SCHEMBL16914545 0.95 KMT2A (0.63) KMT2APMP22ALOX15BLMCYP1A2
Glutamine SCHEMBL15017859 0.95 KMT2A (0.63) KMT2APMP22ALOX15BLMCYP1A2
Glutamine SCHEMBL28025692 0.95 KMT2A (0.63) KMT2APMP22ALOX15BLMCYP1A2
Glutamine SCHEMBL25307133 0.93 KMT2A (0.61) KMT2APMP22ALOX15BLMCYP1A2
Glutamine SCHEMBL6130109 0.93 ALOX15 (0.61) KMT2APMP22ALOX15BLMCYP1A2
Glutamine SCHEMBL22501364 0.93 KMT2A (0.61) KMT2APMP22ALOX15BLMCYP1A2
Glutamine SCHEMBL29060080 0.93 KMT2A (0.61) KMT2APMP22ALOX15BLMCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220192179-A1 BIOMIMETIC ICE-INHIBITING MATERIAL AND CRYOPRESERVATION SOLUTION COMPRISING SAME PEKING UNIVERSITY THIRD HOSPITAL (CN) 2022-06-23 US claimed
EP-3544992-A1 G-PROTEIN-COUPLED RECEPTOR INTERNAL SENSORS The Regents of The University of California (US) 2019-10-02 EP claimed
WO-2018098262-A1 G-PROTEIN-COUPLED RECEPTOR INTERNAL SENSORS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2018-05-31 WO claimed
CN-102245208-B immunoglobulin variants and uses thereof HOFFMAN-LA ROCHE LTD. (CH) 2016-03-16 CN claimed
CN-117180432-A Use of inhibitors of oxidized ATM for the treatment of breast cancer 重庆医科大学 2023-12-08 CN disclosed
US-20230384333-A1 GPCR SCREENING METHOD TO IDENTIFY NON-HALLUCINOGENIC COMPOUNDS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2023-11-30 US disclosed
CN-117015712-A GPCR screening method for identifying non-magic compound 加利福尼亚大学董事会 2023-11-07 CN disclosed
US-20230348557-A1 T cell receptors Targeting Defective DNA Repair Proteins UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION 2023-11-02 US disclosed
EP-4229075-A1 GPCR SCREENING METHOD TO IDENTIFY NON-HALLUCINOGENIC COMPOUNDS The Regents of the University of California (US) 2023-08-23 EP disclosed
EP-4099989-A2 T CELL RECEPTORS TARGETING DEFECTIVE DNA REPAIR PROTEINS University of Pittsburgh - Of the Commonwealth System of Higher Education (US) 2022-12-14 EP disclosed
WO-2022081631-A1 GPCR SCREENING METHOD TO IDENTIFY NON-HALLUCINOGENIC COMPOUNDS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2022-04-21 WO disclosed
WO-2021158962-A2 T CELL RECEPTORS TARGETING DEFECTIVE DNA REPAIR PROTEINS UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2021-08-12 WO disclosed
US-6803203-B1 PROTEIN KINASES; FOR MONITORING IN VITRO ACTIVITY IN EUKARYOTIC CELLS; DRUG SCREENING; KITS BROOKHAVEN SCIENCE ASSOCIATES 2004-10-12 US disclosed
US-6803203-B1 PROTEIN KINASES; FOR MONITORING IN VITRO ACTIVITY IN EUKARYOTIC CELLS; DRUG SCREENING; KITS BROOKHAVEN SCIENCE ASSOCIATES 2004-10-12 US disclosed
WO-2004080920-A1 HYDROPONIC PLANT NUTRIENT KIT AND METHOD OF USE ADVANCED NUTRIENTS LTD. (CA) 2004-09-23 WO disclosed
EP-1309552-A1 COMPOUNDS AND INHIBITORS OF PHOSPHOLIPASES THE UNIVERSITY OF QUEENSLAND (AU) 2003-05-14 EP disclosed
US-20020034570-A1 Cheese flavoring SYMRISE GMBH & CO. KG (DE) 2002-03-21 US disclosed
WO-2002008189-A1 COMPOUNDS AND INHIBITORS OF PHOSPHOLIPASES THE UNIVERSITY OF QUEENSLAND (AU) 2002-01-31 WO disclosed
US-6298858-B1 Tobacco flavoring components of enhanced aromatic content and method of providing same R. J. REYNOLDS TOBACCO COMPANY 2001-10-09 US disclosed
WO-2000028840-A1 TOBACCO FLAVORING COMPONENTS OF ENHANCED AROMATIC CONTENT AND METHOD OF PROVIDING SAME R. J. REYNOLDS TOBACCO COMPANY (US) 2000-05-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220192179-A1 BIOMIMETIC ICE-INHIBITING MATERIAL AND CRYOPRESERVATION SOLUTION COMPRISING SAME IGFBP1, IGFBP2, BCL2L1 KMT2A 4430/4885PMP22 64/4885ALOX15 3949/4885
US-20230384333-A1 GPCR SCREENING METHOD TO IDENTIFY NON-HALLUCINOGENIC COMPOUNDS HTR4, HTR6, HTR1A KMT2A 1949/4885PMP22 1232/4885ALOX15 3974/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.